DIADIA0.73%
SPYSPY0.54%
QQQQQQ0.59%
Trending
Top trending tickerSPCXSPCX19.22%
TRUMPTRUMP29.40%
ROKUROKU20.08%
DIADIA0.73%
PWRL20.27%
NTLANTLA1.94%
RIVNRIVN7.85%
KODKKODK0.31%
UAMYUAMY3.96%
WBDWBD0.45%
Top trending tickerSPCXSPCX19.22%
TRUMPTRUMP29.40%
ROKUROKU20.08%
DIADIA0.73%
PWRL20.27%
NTLANTLA1.94%
RIVNRIVN7.85%
KODKKODK0.31%
UAMYUAMY3.96%
WBDWBD0.45%
homeSymbolIBRXnews
IBRX logo

IBRXImmunityBio Inc

$7.10
$0.10
(1.39%)
Today
Closed $7.10
$0.00
(0.00%)
After Hours
Updated: 07:59 PM EDT
Mkt Cap$7.54B
Vol8.82M
26

Bearish Sentiment

How do you feel about IBRX?

Feed

News

Sentiment

Fundamentals

Info

News
all
press releases
The Multi-Billion-Dollar Race to Defeat Glioblastoma: Why Investors Are Watching One of Oncology's Most Challenging Frontiers
Cancer treatment has advanced dramatically over the past two decades. Precision medicine, immunotherapy, antibody-drug conjugates, and targeted therapies have transformed outcomes for patients across multiple tumor types. $NTHI, $KZIA, $BNTX, $IBRX
24-7 Market News
News Placeholder
More News
News Placeholder
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced two poster presentations and one online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2, 2026, in Chicago. The presentations span two randomized...
Business Wire
News Placeholder
IBRX and the BCG Shortage: Deals That Could Expand Demand
ImmunityBio targets the BCG shortage with new supply deals and label expansion efforts that could strengthen Anktiva demand in bladder cancer.
Zacks
News Placeholder
IBRX Stock Outlook After Q1 Results and a New FDA Review
ImmunityBio eyes a steadier path after a 290% YTD surge as investors watch Anktiva demand, FDA review timing and execution risks.
Zacks
News Placeholder
ImmunityBio: Anktiva Explained and What Comes Next
IBRX's Anktiva drives a 668% revenues jump in 2025 as ImmunityBio expands bladder cancer approvals and pursues new catalysts.
Zacks
News Placeholder
The $13 Million Company Teaching the Immune System to Hunt Cancer
The $13 Million Company Teaching the Immune System to Hunt Cancer The $13 Million Company Teaching the Immune System to Hunt Cancer PR Newswire NEW YORK, May 29, 2026 Issued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)Three drugs in human trials. A platform licensed from one of the world's top...
PR Newswire
News Placeholder
ImmunityBio Deadline Today: Rosen Law Firm Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the Class Period), of the important May 26, 2026 lead plaintiff deadline in the securities class action...
Business Wire
News Placeholder
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. Lawsuit - IBRX
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. Lawsuit - IBRX The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. Lawsuit - IBRX PR Newswire NEW YORK, May 26, 2026 NEW YORK, May 26, 2026...
PR Newswire
News Placeholder
IBRX FINAL DEADLINE REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ImmunityBio, Inc. (ImmunityBio or the Company) (NASDAQ: IBRX) and reminds investors of the May 26, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has...
Business Wire
News Placeholder
IBRX DEADLINE ALERT: ImmunityBio (IBRX) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action -- Hagens Berman
IBRX DEADLINE ALERT: ImmunityBio (IBRX) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action -- Hagens Berman IBRX DEADLINE ALERT: ImmunityBio (IBRX) Investors Alerted to Today's Lead Plaintiff Deadline in Securities Class Action -- Hagens Berman PR Newswire SAN...
PR Newswire
<
1
2
...
>

Advertisement|Remove ads.

Advertisement|Remove ads.